Neuroendocrine Tumor Treatment Market Players:
- BoehringerIngelheim International GmbH
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Hutchison MediPharma Limited,
- AVEO Oncology
- Pfizer, Inc.
- IpsenPharma
- Tarveda Therapeutics
- Progenics Pharmaceuticals
- Novartis AG
- Eli Lilly & Company
- Ipsen Pharma
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of neuroendocrine tumor treatment is assessed at USD 2.99 billion.
The global neuroendocrine tumor treatment market size was valued at more than USD 2.83 billion in 2025 and is expected to register a CAGR of over 6.1%, exceeding USD 5.12 billion revenue by 2035.
North America neuroendocrine tumor treatment market is poised to capture 38% share by 2035, driven by high R&D spending, advanced healthcare infrastructure, and adoption of cutting-edge technologies in healthcare.
Key players in the market include BoehringerIngelheim International GmbH, Hutchison MediPharma Limited, AVEO Oncology, Pfizer, Inc., IpsenPharma, Tarveda Therapeutics, Progenics Pharmaceuticals, Novartis AG, Eli Lilly & Company, Ipsen Pharma.
